The potential synergy benefits from this integration includes multi-specialty capabilities, access to cutting-edge technology in stem-cell therapy and organ transplantation, sharing of medical technologies and know how, exchange of human talent, optimizing costs of operations, high brand equity through integration of premium healthcare brands in Asia as well as a fillip to medical tourism initiatives with multiple options at different price points for customers.

Dr. Lim Cheok Peng, Parkway's Executive Vice Chairman and Chief Executive Officer, added, "We are pleased to welcome Fortis as a new major shareholder of Parkway. There are lots of synergies which Parkway can leverage on and we look forward to working with Fortis to take Parkway to the next level." Religare Capital Markets Plc (The global Investment banking arm of Religare Enterprises Limited) is the sole advisor to Fortis Healthcare Ltd. on this transaction."

Read more: